GoKawiilBedaquiline resistance emerges, threatening WHO's six-month TB regimen
The WHO's 2022-recommended six-month TB treatment, which relies on the antibiotic bedaquiline alongside other pills, is showing signs of drug resistance among patients. Researchers warn this could force a return to the older 20-month regimen involving injectable drugs with severe side effects such as hearing loss. TB remains the world's deadliest infectious disease, killing 1.23 million people in 2024.
GoKawiil's interpretation of the reporting above, not reported fact.
Scientists note that limited understanding of how and why bacterial resistance develops makes it hard to protect newer treatments before they become useless. Researchers argue that antimicrobial R&D should be reframed as a balance between inventing new drugs and generating evidence on preserving existing ones, rather than treating drug discovery and resistance monitoring as separate stages. This suggests future TB control efforts may need to build resistance surveillance directly into drug rollout rather than responding after resistance appears.
- WHO's 2022 six-month bedaquiline-based TB regimen is faster and cheaper than the previous 20-month treatment.
- Emerging drug resistance threatens to push TB treatment back toward the older, harsher injectable regimen.
- Researchers call for integrating resistance-evidence generation into drug development, not treating it as a separate later step.
Source: nature.com — Cehovin, 2026-09-30
Published there as: “Tuberculosis treatment has advanced — now we need to stop drug resistance dragging us backwards”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.